Business Context and Reporting Period
This Form 8-K, dated June 6, 2007, reports on the completion of a tender offer by Greatbatch, Inc. (the "Registrant") to acquire Enpath Medical, Inc. ("Enpath"). The transaction was executed pursuant to a Merger Agreement dated April 28, 2007, involving Greatbatch Ltd. and Chestnut Acquisition Corporation.
Key Financial Metrics and Transaction Details
- Acquisition Price: $14.38 per share in cash.
- Shares Tendered: 5,790,211 shares of Enpath common stock were validly tendered and not withdrawn during the initial offer period.
- Ownership Stake: The Purchaser acquired approximately 90.1% of Enpath's outstanding common stock.
- Payment Terms: Cash payment without interest, less required withholding taxes, to be made promptly.
- Subsequent Offer: A subsequent offering period commenced on June 6, 2007, and expired on June 8, 2007, at the same price of $14.38 per share.
Material Changes and Transaction Structure
Following the expiration of the subsequent offer period, Chestnut Acquisition Corporation will merge with and into Enpath. Upon the effective date of the Merger (expected on or about June 15, 2007), all remaining outstanding shares of Enpath not tendered will automatically convert into the right to receive $14.38 per share in cash. Enpath will continue as the surviving corporation and become a wholly-owned subsidiary of Greatbatch Ltd.
Guidance, Outlook, and Contingencies
The filing does not provide specific financial guidance, management commentary on future operations, or risk factors beyond the standard transaction mechanics. The primary contingency noted is the filing of required financial statements and pro forma financial information for Enpath, which will be submitted by amendment to this Form 8-K on or before August 22, 2007, in accordance with Regulation S-X.
Investor Verification Checklist
- Verify the final percentage of Enpath shares acquired after the subsequent offering period concludes.
- Confirm the exact effective date of the Merger, currently expected on or about June 15, 2007.
- Review the forthcoming amendment (due August 22, 2007) for Enpath's audited financial statements and pro forma financial information.
- Confirm that the total consideration paid aligns with the $14.38 per share rate for all tendered and converted shares.